Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - Information (Details)

v3.19.2
Stock-Based Compensation - Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Stock-Based Compensation        
Number of options granted (in shares)     311,800  
Available for grant (in shares) 388,941   388,941  
Share-based compensation costs recognized $ 1,030 $ 741 $ 1,712 $ 2,060
Employees        
Stock-Based Compensation        
Remaining unamortized expense 4,943   $ 4,943  
Remaining unamortized expense period     1 year 6 months  
Non-Employees        
Stock-Based Compensation        
Remaining unamortized expense 291   $ 291  
Remaining unamortized expense period     9 months 18 days  
Options        
Stock-Based Compensation        
Share-based compensation costs recognized 1,010 669 $ 1,669 1,860
Options | BioXcel Corporation        
Stock-Based Compensation        
Share-based compensation costs recognized $ 20 $ 76 $ 43 $ 199
Options | Employees        
Stock-Based Compensation        
Number of options granted (in shares)     311,800  
Weighted-average grant-date fair value     $ 2,097  
Options | Non-Employees        
Stock-Based Compensation        
Weighted-average grant-date fair value     $ 0